|Description||GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to elevate cAMP in various cell types of the central nervous system. No development was reported for phase-I development in Major depressive disorder and Huntington's-disease.|
|Solubility||Soluble in DMSO|
|Application||Huntington's disease; Major depressive disorder|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator GlaxoSmithKline|
Rolipram is a selective PDE4-inhibitor and an anti-inflammatory agent.
CI-1044, a selective PDE4 inhibitor, inhibits in vitro LPS-induced TNF-alpha release in whole blood from COPD patients better than rolipram and cilomilast and s...
Selective phosphodiesterase 4 (PDE4) inhibitor. Antiasthmatic; used in treatment of chronic obstructive pulmonary disease.
NVP-ABE171 is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D ...
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selec...
GSK256066 2,2,2-trifluoroacetic acid
GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold...
Apremilast (CC-10004)is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneo...
Roflumilast has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such ...
Oglemilast is a potent PDE4 inhibitor and under clinical studies in the treatment of allergen-induced asthma.
MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans...
GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to el...
Ronomilast is type 4 cyclic nucleotide phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
AN3199, a PDE4 inhibitor, was once studied as an anti-inflammatory agent. IC50: 94.5 nM
Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 μM and 0.8 μM respectively.
Crisaborole is a novel PDE-4 inhibitor used as a nonsteroidal topical medication for the treatment of mild-to-moderate atopic dermatitis (eczema). Crisaborole s...
L-869298 is a high potent and selective PDE4 inhibitor, acts as a Type 4 cyclic nucleotide phosphodiesterase inhibitor.
Tilivapram, a pyridine derivative, has been found to be a phosphodiesterase IV inhibitor that could probably be used in studying its bioactivities in sorts of a...
S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous ...
CP-220629, a Pyrazolopyridin derivative, has been found to be a Type 4 cyclic nucleotide phosphodiesterase inhibitor that was once studied as an anti-inflammato...
MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition.